Although the Anacetrapib CVOT was nominally positive (#msg-134215022), the very modest clinical benefit (MACE HR=0.91 vs placebo) nullified any realistic chance for the drug to be a commercial success.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.